We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
EOM Pharmaceutical Holdings Inc (PK) | USOTC:IMUC | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.06 | 40.00% | 0.21 | 0.06 | 0.55 | 0.21 | 0.21 | 0.21 | 100 | 21:15:35 |
EOM PHARMACEUTICAL HOLDINGS, INC.
136 Summit Avenue
Montvale, NJ 07645
August 2, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | EOM Pharmaceutical Holdings, Inc. | |
(formerly known as Immunocellular Therapeutics, Ltd.) | ||
Request for Withdrawal of Registration Statement on Form S-1 | ||
Filed on June 24, 2022 | ||
File No. 333-265817 |
Ladies and Gentlemen:
Pursuant to Rule 477 of the Securities Act of 1933, as amended (“Securities Act”), EOM Pharmaceutical Holdings, Inc., a Delaware corporation (formerly known as Immunocellular Therapeutics, Ltd., the “Company”), hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the Registration Statement on Form S-1 (File No. 333-265817), together with all exhibits and amendments thereto, as initially filed with the Commission on June 24, 2022 (collectively, “Registration Statement”), effective immediately or at the earliest practicable date hereafter.
The Company is seeking withdrawal of the Registration Statement because it opted not to pursue the offering contemplated thereby. The Company confirms that the Registration Statement has not been declared effective and that no securities have been sold pursuant to the Registration Statement.
Accordingly, the Company requests that the Commission issue an order granting the withdrawal of the Registration Statement (the “Order”) effective as of the date hereof or at the earliest practicable date hereafter. Please provide a copy of the Order to the undersigned at the above address, with a copy to Louis A. Brilleman, counsel for the Company, via email at lbrilleman@lbcounsel.com.
Additionally, in accordance with Rule 457(p) of the Securities Act, the Company requests that all fees paid to the Commission in connection with the initial filing of the Registration Statement be credited for future use by the Company.
Should you have any questions regarding this request for withdrawal, or if you require any additional information, please contact Louis A. Brilleman by telephone at (212) 537-5852.
Very truly yours, | ||
/s/ Eli Goldberger | ||
Name: | Eli Goldberger | |
Title: | Chairman |
1 Year EOM Pharmaceutical (PK) Chart |
1 Month EOM Pharmaceutical (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions